We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > News > Science & Health > Content Piece

Positive Progress Made in Cannabis for Chronic Pain Study

Published: Apr 13, 2018   

Credit: Pixabay

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

Tetra Bio-Pharma has provided a status report on its encapsulated cannabis oils clinical trials and that these cannabis products are ready for the retail market post-legalization.

Natural health products and OTC medications

The authorization from the Office of Controlled Substances marks the initiation of the treatment phase of the Phase 2 clinical trial that will be used to support Product License Applications post-legalization. Tetra is performing this clinical study to obtain safety and efficacy data to support modern claims for the use of encapsulated cannabis oils in the treatment of chronic pain. Tetra's products are being developed to be compliant with standards expected for pharmaceutical products which will be supported by scientific and clinical evidence.

PPP005 Phase 1 Clinical trial

Phase 1 clinical trials to assess safety, tolerability and pharmacokinetics of single and multiple dose of encapsulated cannabis oil (10 mg THC with 10 mg CBD) will be completed soon. "This study will provide cardiovascular safety data to ensure that the oil formulations can be safely used by consumers. The pharmacokinetic data will provide the data required to define the frequency of dosing needed to avoid inappropriate use that could lead to accumulation of cannabinoids in the body," said Dr. Guy Chamberland, M.Sc., Ph.D., interim CEO and Chief Scientific Officer.

PPP005 Phase 2 Clinical trial

On March 22, 2018, Santé Cannabis, the Montreal-based clinic that is conducting the Phase 2 clinical trial for Tetra, received authorization from the Office of Controlled Substances to use the cannabis oil capsules. 

This authorization allowed the Principal Investigator of the trial, Dr. Antonio Vigano, to proceed with the clinical trial of PPP005 in chronic pain patients. This exemption allows Santé Cannabis to prescribe the blinded study medication and for Aphria Inc to ship blinded products to patient's home under the jurisdiction of the ACMPR. The screening and enrolment is proceeding faster than expected and will allow Tetra to meet its corporate objectives.

"We are performing this Phase 2 clinical trial to obtain safety and efficacy data to help drive the sales of encapsulated cannabis oil products for the treatment of chronic pain," added Dr. Guy Chamberland. "We expect chronic pain patients to use cannabis oils, but many of these patients will also be taking opioids or other prescription medications. The capability of different doses and ratios of medical cannabis oil to change the amount and type of concomitant medications, such as opioids, used for pain, and the need for rescue pain medication to control chronic non-cancer and cancer pain is evaluated. The use of measures that quantify different pain drug regimens used by the patients will help us understand the potential of cannabis oils to be used for opioid sparing. The trial should be completed by fall 2018."

This article has been republished from materials provided by Tetra Bio-Pharma. Note: material may have been edited for length and content. For further information, please contact the cited source.


Like what you just read? You can find similar content on the topic tag shown below.

Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter